# Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

> **NCT05826275** · PHASE1 · COMPLETED · sponsor: **Toragen, Inc.** · enrollment: 28 (actual)

## Conditions studied

- HPV Associated Cancers

## Interventions

- **DRUG:** TGN-S11
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05826275
- **Lead sponsor:** Toragen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-20
- **Primary completion:** 2025-05-28
- **Final completion:** 2025-06-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05826275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05826275, "Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05826275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*